Trans-scleral diode laser cyclophotocoagulation for refractory XXXX after high-risk penetrating keratoplasty.

@entity1 @entity409 @entity726
UNASSIGNED: To analyze the intraocular pressure reduction, number of anti- @entity726 medications needed, and post-operative complications of trans-scleral diode laser cyclophotocoagulation (DCPC) in @entity1 with high-risk penetrating keratoplasty (PKP) and secondary refractory @entity726 . Prospective interventional, longitudinal, non-comparative series of cases, including 16 eyes of 15 @entity1 's post-PKP on maximal anti- @entity726 medical therapy with intraocular pressures above 22  mmHg. All @entity1 received 18 shots, 360   peri-limbal (avoiding the long posterior ciliary nerves and arteries at 3 and 9 o'clock positions) of trans-scleral DCPC (2000  mW, time: 2.0  s/shot). There was a 55.5  % reduction (total of 14.0  mmHg) of the mean pre-operative IOP (31.5  mmHg) after the first diode laser application (p  =  0.0020). Re-treatment was required in 31.2  % of eyes over a mean period of 10.7  months. In these five eyes, the mean pre-operative IOP was 40.4  mmHg, which decreased to 15.0  mmHg post-therapy, and a mean IOP reduction of 25.4  mmHg (p  =  0.0218). There was a 51.0  % reduction in the mean number of medications used after the first, and a 57.1  % reduction after a second laser application. The incidence of failure (IOP  >=   22  mmHg or need of additional medical therapy) from initial intervention to loss of follow-up was 1.3  % per @entity1 -month. DCPC effectively reduces the intraocular pressure and the number of anti- @entity726 medications with few complications in @entity1 after high-risk PKP and @entity726 . Only, one-third of the eyes needed a second intervention to control the intraocular pressure. Post-DCPC complications were limited to phthisis bulbi and @entity409 , one eye each. Please check and confirm the author names and initials are correct. Also, kindly confirm the details in the metadata are correct.
